

Date of the CVA	07/04/2020
-----------------	------------

Section A. PERSONAL DATA

Name and Surname	Luke Adam Noon		
DNI	Y0371536-P	Age	42
Researcher's identification number	Researcher ID	H-4141-2014	
	Scopus Author ID		
	ORCID	0000-0002-0502-4322	

A.1. Current professional situation

Institution	Centro de Investigación Príncipe Felipe		
Dpt. / Centre			
Address			
Phone	(34) 963289680 - 3211	Email	l.noon@cipf.es
Professional category	Investigador Principal	Start date	2020
UNESCO spec. code			
Keywords			

A.2. Academic education (Degrees, institutions, dates)

Bachelor/Master/PhD	University	Year
Doctor of Philosophy (PhD)	University of London, Queen Mary and Westfield College, England	2005
Master of Science (MSc) with Distinction in Advanced Methods in Taxonomy and Biodiversity	Imperial College, University of London	2000
Bachelor of Science (BSc), 1st Class Honours Zoology	Durham University, England	1999

A.3. General quality indicators of scientific production

Section B. SUMMARY OF THE CURRICULUM

Section C. MOST RELEVANT MERITS (ordered by typology)

C.1. Publications

- Scientific paper.** Manzano-Nunez, Fatima; et al. 2019. Insulin resistance disrupts epithelial repair and niche-progenitor Fgf signaling during chronic liver injury PLOS BIOLOGY. PUBLIC LIBRARY SCIENCE. 17-1. ISSN 1545-7885.
- Scientific paper.** Senan, O.; et al. 2019. CliqueMS: A computational tool for annotating in-source metabolite ions from LC-MS untargeted metabolomics data based on a coelution similarity network. Bioinformatics (Oxford, England). ISSN 1367-4811.
- Scientific paper.** Lee, Youngmin A.; et al. 2018. Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap NATURE COMMUNICATIONS. NATURE PUBLISHING GROUP. 9. ISSN 2041-1723.
- Scientific paper.** Lou, Yan-Ru; et al. 2014. The Use of Nanofibrillar Cellulose Hydrogel As a Flexible Three-Dimensional Model to Culture Human Pluripotent Stem Cells STEM CELLS AND DEVELOPMENT. MARY ANN LIEBERT, INC. 23-4, pp.380-392. ISSN 1547-3287.
- Scientific paper.** [Lade, Abigale]*co-author; [Noon, Luke A.]*co-author; Friedman, Scott L. 2014. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer CURRENT OPINION IN ONCOLOGY. 26-1, pp.100-107. ISSN 1040-8746.

- 6 **Scientific paper.** [Napoli, Ilaria]*co-author; et al. 2012. A Central Role for the ERK-Signaling Pathway in Controlling Schwann Cell Plasticity and Peripheral Nerve Regeneration In Vivo NEURON. CELL PRESS. 73-4, pp.729-742. ISSN 0896-6273.
- 7 **Scientific paper.** Feber, Andrew; et al. 2011. Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors GENOME RESEARCH. COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT. 21-4, pp.515-524. ISSN 1088-9051.
- 8 **Scientific paper.** Danovi, Davide; et al. 2010. A Genetic Screen for Anchorage-Independent Proliferation in Mammalian Cells Identifies a Membrane-Bound Neuregulin PLOS ONE. PUBLIC LIBRARY SCIENCE. 5-7. ISSN 1932-6203.
- 9 **Scientific paper.** [Parrinello, Simona]*co-author; et al. 2008. NF1 loss disrupts Schwann cell-axonal interactions: a novel role for semaphorin 4F GENES & DEVELOPMENT. COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT. 22-23, pp.3335-3348. ISSN 0890-9369.
- 10 **Scientific paper.** Parkinson, David B.; et al. 2008. c-Jun is a negative regulator of myelination JOURNAL OF CELL BIOLOGY. ROCKEFELLER UNIV PRESS. 181-4, pp.625-637. ISSN 0021-9525.
- 11 **Scientific paper.** Noon, Luke A.; Lloyd, Alison C.2007. Treating leprosy: an Erb-al remedy? TRENDS IN PHARMACOLOGICAL SCIENCES. ELSEVIER SCIENCE LONDON. 28-3, pp.103-105. ISSN 0165-6147.
- 12 **Scientific paper.** Noon, Luke A.; et al. 2006. A CCAAT/enhancer-binding protein site at-87 is required for the activation of a novel murine melanocortin 2-receptor promoter at late stages during adipogenesis ENDOCRINOLOGY. ENDOCRINE SOC. 147-12, pp.6019-6026. ISSN 0013-7227.
- 13 **Scientific paper.** Noon, Luke A.; et al. 2006. Identification of a novel melanocortin 2 receptor splice variant in murine adipocytes: implications for post-transcriptional control of expression during adipogenesis JOURNAL OF MOLECULAR ENDOCRINOLOGY. SOC ENDOCRINOLOGY. 37-3, pp.415-420. ISSN 0952-5041.
- 14 **Scientific paper.** Noon, Luke A; Lloyd, Alison C. 2005. Hijacking the ERK signaling pathway: Mycobacterium leprae shuns MEK to drive the proliferation of infected Schwann cells.Science's STKE : signal transduction knowledge environment. 2005-309, pp.pe52. ISSN 1525-8882.
- 15 **Scientific paper.** Noon, LA; Clark, AJL; Peter, JK. 2004. A peroxisome proliferator-response element in the murine mc2-r promoter regulates its transcriptional activation during differentiation of 3T3-L1 adipocytes JOURNAL OF BIOLOGICAL CHEMISTRY. AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC. 279-22, pp.22803-22808. ISSN 0021-9258, ISSN 1083-351X.
- 16 **Scientific paper.** Swords, FM; et al. 2004. Constitutive activation of the human ACTH receptor resulting from a synergistic interaction between two naturally occurring missense mutations in the MC2R gene MOLECULAR AND CELLULAR ENDOCRINOLOGY. ELSEVIER IRELAND LTD. 213-2, pp.149-154. ISSN 0303-7207.
- 17 **Scientific paper.** Clark, AJ.; et al. 2003. Expression, desensitization, and internalization of the ACTH receptor (MC2R).Annals of the New York Academy of Sciences. 994, pp.111-117. ISSN 0077-8923.
- 18 **Scientific paper.** Noon, LA; et al. 2002. Failed export of the adrenocorticotrophin receptor from the endoplasmic reticulum in non-adrenal cells: evidence in support of a requirement for a specific adrenal accessory factor JOURNAL OF ENDOCRINOLOGY. BIOSCIENTIFICA LTD. 174-1. ISSN 0022-0795, ISSN 1479-6805.
- 19 **Scientific paper.** Baig, AH; et al. 2001. Desensitization of the Y1 cell adrenocorticotropin receptor - Evidence for a restricted heterologous mechanism implying a role for receptor-effector complexes JOURNAL OF BIOLOGICAL CHEMISTRY. AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC. 276-48, pp.44792-44797. ISSN 0021-9258.

C.2. Participation in R&D and Innovation projects

- 1 Local insulin-induced paracrine signalling (“LiiPS”) in regenerative medicine and cancer Conselleria de Sanidad Universal y Salud Pública. Luke A. Noon. (Centro de Investigación Príncipe Felipe). 01/04/2020-31/12/2023. 58.950 €.

- 2 P.I.04/2017CIPF, Mechanisms of Local Autophagy Inhibition: Targets for Therapeutic Intervention in Chronic Liver Disease CIPF Proyectos de Investigación Intergrupos e Interprograma P.I.04/2017. Luke Noon. (Centro de Investigación Príncipe Felipe). 12/05/2017-11/05/2021. 91.240 €.
- 3 Measuring the impact of insulin resistance on epithelial defence against cancer (EDAC) Special Joint Research Program: Hokkaido University Japón. Luke Noon. (Institute for Genetic Medicine Hokkaido University). 01/04/2017-31/03/2018. 8.000 €.
- 4 Local insulin signalling in the liver (SIL-iver) BFU2014-58686-P Ministerio de Ciencia e Innovación. Investigación. Luke Noon. (CIBER DEL AREA DE DIABETES Y ENFERMEDADES METABOLICAS (CIBERDEM)). 01/01/2015-31/12/2017. 120.000 €.
- 5 SAF2011-28331, The Regulation of Progenitor Cells by Insulin/IRS2 Signaling: Implications for Metabolic Diseases Ministerio de Economía y Competitividad. Luke Noon. (Centro de Investigación Biomédica en Red). 01/01/2012-31/12/2014. 181,5 €. Co-ordinator.
- 6 DIATRIN 267248, Insulin Signalling and the role of IRS proteins in Liver Fibrosis Marie Curie FP7-People-2010-COFUND. Luke Noon. (Mount Sinai School of Medicine). 14/01/2013-14/01/2014. 52.740 €. Co-ordinator.

C.3. Participation in R&D and Innovation contracts

C.4. Patents